Exact Mass: 509.1299958000001

Exact Mass Matches: 509.1299958000001

Found 208 metabolites which its exact mass value is equals to given mass value 509.1299958000001, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

N6,N6,O-Tridemethylpuromycin-5-phosphate

C19H24N7O8P (509.1423914)

NK 250

Bis(pyridin-4-ylmethyl) 2,6-dimethyl-4-(6-methyl-2,3-dihydro-1,4-dithiin-5-yl)-1,4-dihydropyridine-3,5-dicarboxylate

C26H27N3O4S2 (509.14429020000006)

Fluphenazine hydrochloride

Fluphenazine (dihydrochloride)

C22H28Cl2F3N3OS (509.12821340000005)

D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent

4-cis-Hydroxycyclohexyl glyburide

5-chloro-2-methoxy-N-(2-{4-[({[(1s,4s)-4-hydroxycyclohexyl]-C-hydroxycarbonimidoyl}amino)sulfonyl]phenyl}ethyl)benzene-1-carboximidic acid

C23H28ClN3O6S (509.1387258000001)

4-cis-Hydroxycyclohexyl glyburide is a metabolite of glyburide. Glibenclamide, also known as glyburide (USAN), is an antidiabetic drug in a class of medications known as sulfonylureas, closely related to sulfa drugs. It was developed in 1966 in a cooperative study between Boehringer Mannheim (now part of Roche) and Hoechst (now part of Sanofi-Aventis). (Wikipedia)

Dide-O-methyl-4-O-alpha-D-glucopyranosylsimmondsin

2-[(1E)-2,3-dihydroxy-4,6-bis({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})cyclohexylidene]acetonitrile

C20H31NO14 (509.1744466)

Dide-O-methyl-4-O-alpha-D-glucopyranosylsimmondsin is found in coffee and coffee products. Dide-O-methyl-4-O-alpha-D-glucopyranosylsimmondsin is a constituent of jojoba meal (Simmonsia chinensis). Constituent of jojoba meal (Simmonsia chinensis). Di-demethylsimmondsin 4-alpha-D-glucoside is found in coffee and coffee products, fats and oils, and nuts.

2-trans-Hydroxycyclohexyl glyburide

5-chloro-N-(2-{4-[({[(1S,2S)-2-hydroxycyclohexyl]-C-hydroxycarbonimidoyl}amino)sulfonyl]phenyl}ethyl)-2-methoxybenzene-1-carboximidic acid

C23H28ClN3O6S (509.1387258000001)

2-trans-Hydroxycyclohexyl glyburide is a metabolite of glyburide. Glibenclamide, also known as glyburide (USAN), is an antidiabetic drug in a class of medications known as sulfonylureas, closely related to sulfa drugs. It was developed in 1966 in a cooperative study between Boehringer Mannheim (now part of Roche) and Hoechst (now part of Sanofi-Aventis). (Wikipedia)

4-trans-Hydroxycyclohexyl glyburide

5-chloro-2-methoxy-N-(2-{4-[({[(1r,4r)-4-hydroxycyclohexyl]-C-hydroxycarbonimidoyl}amino)sulfonyl]phenyl}ethyl)benzene-1-carboximidic acid

C23H28ClN3O6S (509.1387258000001)

4-trans-Hydroxycyclohexyl glyburide is a metabolite of glyburide. Glibenclamide, also known as glyburide (USAN), is an antidiabetic drug in a class of medications known as sulfonylureas, closely related to sulfa drugs. It was developed in 1966 in a cooperative study between Boehringer Mannheim (now part of Roche) and Hoechst (now part of Sanofi-Aventis). (Wikipedia)

3-trans-Hydroxycyclohexyl glyburide

5-chloro-N-(2-{4-[({[(1R,3R)-3-hydroxycyclohexyl]-C-hydroxycarbonimidoyl}amino)sulfonyl]phenyl}ethyl)-2-methoxybenzene-1-carboximidic acid

C23H28ClN3O6S (509.1387258000001)

3-trans-Hydroxycyclohexyl glyburide is a metabolite of glyburide. Glibenclamide, also known as glyburide (USAN), is an antidiabetic drug in a class of medications known as sulfonylureas, closely related to sulfa drugs. It was developed in 1966 in a cooperative study between Boehringer Mannheim (now part of Roche) and Hoechst (now part of Sanofi-Aventis). (Wikipedia)

3-cis-Hydroxycyclohexyl glyburide

5-chloro-N-(2-{4-[({[(1R,3S)-3-hydroxycyclohexyl]-C-hydroxycarbonimidoyl}amino)sulfonyl]phenyl}ethyl)-2-methoxybenzene-1-carboximidic acid

C23H28ClN3O6S (509.1387258000001)

3-cis-Hydroxycyclohexyl glyburide is a metabolite of glyburide. Glibenclamide, also known as glyburide (USAN), is an antidiabetic drug in a class of medications known as sulfonylureas, closely related to sulfa drugs. (Wikipedia)

3-Hydroxyglibenclamide

5-chloro-N-{2-[4-({[(3-hydroxycyclohexyl)carbamoyl]amino}sulfonyl)phenyl]ethyl}-2-methoxybenzamide

C23H28ClN3O6S (509.1387258000001)

Flumethrin

cyano(4-fluoro-3-phenoxyphenyl)methyl 3-[2-chloro-2-(4-chlorophenyl)ethenyl]-2,2-dimethylcyclopropane-1-carboxylate

C28H22Cl2FNO3 (509.09606940000003)

rac trans-4-Hydroxy Glyburide

5-Chloro-N-{2-[4-({[(4-hydroxycyclohexyl)-C-hydroxycarbonimidoyl]amino}sulphonyl)phenyl]ethyl}-2-methoxybenzene-1-carboximidic acid

C23H28ClN3O6S (509.1387258000001)

3-OxoUndecanoyl-CoA

(2S)-2-{[(2S)-2-{[(2R)-2-{[(2S)-2-amino-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene]amino}-1-hydroxy-3-selanylpropylidene]amino}-1-hydroxy-4-methylpentylidene]amino}-4-methylpentanoate

C19H35N5O6Se (509.175242)

3-oxoundecanoyl-coa is an acyl-CoA or acyl-coenzyme A. More specifically, it is a 3-oxoundecanoic acid thioester of coenzyme A. 3-oxoundecanoyl-coa is an acyl-CoA with 11 fatty acid group as the acyl moiety attached to coenzyme A. Coenzyme A was discovered in 1946 by Fritz Lipmann (Journal of Biological Chemistry (1946) 162 (3): 743–744) and its structure was determined in the early 1950s at the Lister Institute in London. Coenzyme A is a complex, thiol-containing molecule that is naturally synthesized from pantothenate (vitamin B5), which is found in various foods such as meat, vegetables, cereal grains, legumes, eggs, and milk. More specifically, coenzyme A (CoASH or CoA) consists of a beta-mercaptoethylamine group linked to the vitamin pantothenic acid (B5) through an amide linkage and 3-phosphorylated ADP. Coenzyme A is synthesized in a five-step process that requires four molecules of ATP, pantothenate and cysteine. It is believed that there are more than 1100 types of acyl-CoA’s in the human body, which also corresponds to the number of acylcarnitines in the human body. Acyl-CoAs exists in all living species, ranging from bacteria to plants to humans. The general role of acyl-CoA’s is to assist in transferring fatty acids from the cytoplasm to mitochondria. This process facilitates the production of fatty acids in cells, which are essential in cell membrane structure. Acyl-CoAs are also susceptible to beta oxidation, forming, ultimately, acetyl-CoA. Acetyl-CoA can enter the citric acid cycle, eventually forming several equivalents of ATP. In this way, fats are converted to ATP -- or biochemical energy. Acyl-CoAs can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain acyl-CoAs; 2) medium-chain acyl-CoAs; 3) long-chain acyl-CoAs; and 4) very long-chain acyl-CoAs; 5) hydroxy acyl-CoAs; 6) branched chain acyl-CoAs; 7) unsaturated acyl-CoAs; 8) dicarboxylic acyl-CoAs and 9) miscellaneous acyl-CoAs. Short-chain acyl-CoAs have acyl-groups with two to four carbons (C2-C4), medium-chain acyl-CoAs have acyl-groups with five to eleven carbons (C5-C11), long-chain acyl-CoAs have acyl-groups with twelve to twenty carbons (C12-C20) while very long-chain acyl-CoAs have acyl groups with more than 20 carbons. 3-oxoundecanoyl-coa is therefore classified as a medium chain acyl-CoA. The oxidative degradation of fatty acids is a two-step process, catalyzed by acyl-CoA synthetase/synthase. Fatty acids are first converted to their acyl phosphate, the precursor to acyl-CoA. The latter conversion is mediated by acyl-CoA synthase. Three types of acyl-CoA synthases are employed, depending on the chain length of the fatty acid. 3-oxoundecanoyl-coa, being a medium chain acyl-CoA is a substrate for medium chain acyl-CoA synthase. The second step of fatty acid degradation is beta oxidation. Beta oxidation occurs in mitochondria and, in the case of very long chain acyl-CoAs, the peroxisome. After its formation in the cytosol, 3-OxoUndecanoyl-CoA is transported into the mitochondria, the locus of beta oxidation. Transport of 3-OxoUndecanoyl-CoA into the mitochondria requires carnitine palmitoyltransferase 1 (CPT1), which converts 3-OxoUndecanoyl-CoA into 3-OxoUndecanoylcarnitine, which gets transported into the mitochondrial matrix. Once in the matrix, 3-OxoUndecanoylcarnitine is converted back to 3-OxoUndecanoyl-CoA by CPT2, whereupon beta-oxidation can begin. Beta oxidation of 3-OxoUndecanoyl-CoA occurs in four steps. First, since 3-OxoUndecanoyl-CoA is a medium chain acyl-CoA it is the substrate for a medium chain acyl-CoA dehydrogenase, which catalyzes dehydrogenation of 3-OxoUndecanoyl-CoA, creating a double bond between the alpha and beta carbons. FAD is the hydrogen acceptor, yielding FADH2. Second, Enoyl-CoA hydrase catalyzes the addition of water across the newly formed double bond to make an alcohol. Third, 3-hydroxyacyl-CoA dehydrogenase oxidizes the alcohol group to a ketone and NADH is produc...

Ripretinib

N-{4-bromo-5-[1-ethyl-7-(methylimino)-2-oxo-1,2,6,7-tetrahydro-1,6-naphthyridin-3-yl]-2-fluorophenyl}-n-phenylcarbamimidate

C24H21BrFN5O2 (509.0862558)

((2R,3R,4S,5R)-5-(2-amino-6-oxo-1,6-dihydropurin-9-yl)-4-hydroxy-3-((2R,4S,5S)-3,4,5-trihydroxy-6-methyl-tetrahydro-2H-pyran-2-yloxy)-tetrahydrofuran-2-yl)methyl hydrogen sulfate

C16H23N5O12S (509.10638780000005)

bilain C

C23H31N3O6S2 (509.1654186)

Miriamide 5-glucoside

C22H23NO13 (509.1169348)

jorunnamycin B

C26H27N3O8 (509.17980620000003)

frenolicin C

C23H27NO10S (509.1355602000001)

Evista

Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-, hydrochloride (1:1)

C28H28ClNO4S (509.1427478000001)

Raloxifene hydrochloride is a hydrochloride salt resulting from the reaction of equimolar amounts of raloxifene and hydrogen chloride. It has a role as a bone density conservation agent, an estrogen antagonist and an estrogen receptor modulator. It contains a raloxifene(1+). Raloxifene Hydrochloride is the hydrochloride salt form of raloxifene, a selective benzothiophene estrogen receptor modulator (SERM) with lipid lowering effects and activity against osteoporosis. Raloxifene hydrochloride specifically binds to estrogen receptors in responsive tissue, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it promotes or suppresses the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. This agent functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In tissue like bone, it decreases bone resorption and bone turnover and increases bone mineral density. Raloxifene hydrochloride acts as an estrogen antagonist in uterine and breast tissue. This agent also exerts an anti-proliferative effect on estrogen-sensitive breast cancer. A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue. See also: Raloxifene (has active moiety). D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D050071 - Bone Density Conservation Agents C1892 - Chemopreventive Agent Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation?selective and orally active estrogen receptor modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue[1].

Raloxifene Hcl

Evista (Raloxifene Hydrochloride)

C28H28ClNO4S (509.1427478000001)

D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D050071 - Bone Density Conservation Agents C1892 - Chemopreventive Agent Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation?selective and orally active estrogen receptor modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue[1].

(Methylsulfonyl)octyl glucosinolate

C16H31NO11S3 (509.1059176)

Annotation level-3

Ala Cys Met Trp

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-aminopropanamido]-3-sulfanylpropanamido]-4-(methylsulfanyl)butanamido]-3-(1H-indol-3-yl)propanoic acid